Q3 Fiscal 2026 Highlights (compared to Q3 Fiscal year 2025)Record net income of $1.4 million versus net loss of $(1.0) million in Q3 FY2025 Operating expenses reduced 18% year-over-year, driving operating income of $1.7 million and 17% operating margin Adjusted EBITDA of $3.0 million (29% margin), up from $1.7 million (15% margin) in the prior-year quarter 2 Fifth consecutive quarter of positive operating cash flow, reaching $1.0 millionPHOENIX, March 16, 2026 (GLOBE NEWSWIRE) — Aspen Group, Inc. (OTCQB: ASPU) (“AGI” or the “Company”), an education technology holding company, today announced financial results for its third quarter of fiscal year 2026 ended January 31, 2026. Third Quarter Fiscal Year 2026 Summary Results  Three Months Ended January 31,   Nine Months Ended January 31,$ in millions, except per share data...

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced business updates and reported financial results for the fiscal year 2025. In 2025, Annovis achieved a significant milestone in its clinical development program with the initiation of a pivotal Phase 3 clinical trial in early AD. The year was largely dedicated to the activation of clinical sites and the enrollment of participants across the United States. The Company also reported encouraging data from both its previous Alzheimer’s and Parkinson’s programs, demonstrating a potential disease-modifying...

2025 Total Revenue and Adjusted EBITDA1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026  Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA1 of $18 million and Adjusted EBITDA Margin1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year...

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients with frontline ER+/HER2- metastatic breast cancer Initiated the Phase 1b/2 study of palazestrant in combination with Pfizer’s novel CDK4 inhibitor, atirmociclib, in patients with ER+/HER2- metastatic breast cancer Continued enrollment in the Phase 1 clinical study of OP-3136 in breast cancer and other solid tumors, with initial clinical data expected in Q2 2026 Generated $218.5 million in gross proceeds from a follow-on public offering, further strengthening the Company’s balance sheet; ended 2025 with $505.4 million in cash, cash equivalents,...

– Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results – – Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 – – New, half-life extended anti-CD-19 and FcγRIIb mAb (ZB014) progressing toward clinical development – – Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis (MS) ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 – – Oral, IL-17AA/AF inhibitor (ZB021) Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end – – Up to $250 million non-dilutive, multi-tranche debt financing secured from Pharmakon...

– Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) – – FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC – – Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 – – Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 – – Company to host conference call today at 8 a.m. ET / 5 a.m. PT – SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in...

Q4 FY26 revenues of $1.75 billion; FY26 revenues of $7.26 billion Q4 FY26 net income of $85 million, adjusted EBITDA(1) of $181 million or 10.3% of revenue; FY26 net income of $358 million, adjusted EBITDA(1) of $708 million or 9.7% of revenue Q4 FY26 diluted earnings per share of $1.87, adjusted diluted earnings per share(1) of $2.62; FY26 diluted earnings per share of $7.70, adjusted diluted earnings per share(1) of $10.75 Q4 FY26 cash flows provided by operating activities of $258 million, free cash flow(1) of $336 million; FY26 cash flows provided by operating activities of $609 million, free cash flow(1) of $577 million Q4 FY26 net bookings of $0.6 billion; book-to-bill ratio of 0.3; trailing twelve months book-to-bill ratio of 1.1 Announces FY27 guidance for adjusted diluted earnings per share(1) and reiterates revenue, adjusted...

Roblon’s revenue and earnings for the first quarter of 2025/26 fell short of Management’s guidance at the beginning of the financial year The Board of Directors of Roblon A/S has today considered and approved the interim report for the first three months of 2025/26. Highlights Q1 2025/26 Consolidated revenue amounted to DKKm 29.8, against DKKm 51.1 in the year-earlier period. Whereas the FOC product group improved, the revenue decline in the Composite area was more pronounced than expected. EBITDA before special items was a loss of DKKm 6.3 (a profit of DKKm 6.7). EBIT before special items was a loss of DKKm 9.2 (a profit of DKKm 3.0), and profit/loss from continuing operations before tax was a loss of DKKm 10.4 (a profit of DKKm 4.6). While Management did expect a lower level of activity in the first quarter of 2025/26, both revenue...

— Fourth Quarter Revenues of RMB 676.2 million, down 17.4% year over year — Fourth Quarter Net Loss of RMB 88.1 million, compared with RMB 72.5 million in the same period of 2024 — Full Year Revenues of RMB 4,307.9 million, up 31.0% year over year — Full Year Net Loss of RMB 39.4 million, compared with RMB 193.2 million in 2024 BEIJING, March 16, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsRevenues were RMB 676.2 million, a decrease of 17.4% year over year Gross margin was 15.3%, compared with 12.4% in the fourth quarter of 2024 Net loss was RMB 88.1 million,...

Urgently Delivers Q4 2025 Revenue Growth, Margin Expansion, GAAP Operating Loss Reduction and Non-GAAP Operating Income ASHBURN, Va., March 13, 2026 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today reported financial results for the fourth quarter and year ended December 31, 2025. “We’re pleased to report continued progress and positive momentum in our financial performance. In the fourth quarter, revenue grew 4% year-over-year, gross profit increased 23% to $8.7 million, and gross margin expanded to 26%, which was a 4-point improvement over the prior year period,” said Matt Booth, CEO of Urgently. “For the full year, we significantly reduced operating expenses by delivering an improvement of 29% in GAAP operating...